Abstract Library

#3926 Epidemiology and outcomes of NET in a Portuguese cancer center

Introduction: NET make up 0.5% of all cancer diagnosis in Europe. They range from indolent to highly aggressive tumors and may cause a wide range of functional symptoms. Phase III trials are difficult because of poor accrual in a heterogenous group of rare tumors.

Conference:

Presenting Author: Magno S

Authors: Magno S, Esteves S, Leite V, Claro I, Pereira D,

Keywords: neuroendocrine, epidemiology, portugal, outcomes,

#1823 Effects of Low-Doses Aspirin on Clinical Outcome and Disease Progression in Patients with Gastro-Entero-Pancreatic Neuroendocrine Tumors: Results of a Multicentric Retrospective Study

Introduction: The chemopreventive effect of aspirin (ASA) have been observed in the setting of colorectal cancer. The impact of aspirin use on clinical outcome of patients with gastro-entero-pancreatic neuroendocrine neoplasms (GEP NEN) has not been evaluated yet

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Cavalcoli F

Authors: Massironi S, Pusceddu S, Cavalcoli F, Zilli A, Tamagno G,

Keywords: NEN, ASA,

#1403 A Univariate Analysis of Factors Influencing Survival in Advanced Pancreatic Neuroendocrine Tumors

Introduction: Pancreatic neuroendocrine tumors (pNET) are rare and display clinical heterogeneity.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Jann H

Authors: Jimenez-Fonseca P, Monleón Getino A, Krug S, Fierro Maya F, Tamagno G,

Keywords: pNET, prognosis,

#1361 Evaluation of the Therapeutic Approaches Impacting on the Survival of Patients with an Advanced Pancreatic Neuroendocrine Tumor

Introduction: The therapeutic approaches in metastatic pancreatic neuroendocrine tumors (pNET) are currently used as a palliative strategy to control symptoms and potentially improving patient survival.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Krug S

Authors: Krug S, Tamagno G, Jann H, Jimenez-Fonseca P, Costa F,

Keywords: pNET,

#992 Phase 1 and Phase 2 Clinical Trials Investigating Targets Against the Molecular Hallmarks of Gastroenteropancreatic Neuroendocrine Tumors

Introduction: Recently there have been many advances in the diagnosis and treatment of gastroenteropancreatic neuroendocrine tumors (GEP NETs), accompanied by significant improvements in our understanding of GEP NET biology. A number of well-established or novel molecular hallmarks are involved in GEP NET tumorigenesis and may help in identifying potential diagnostic or therapeutic targets.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author: Tamagno G

Authors: Tamagno G, Crespo G, Fierro Maya F, Fossmark R, Igaz P,

Keywords: neuroendocrine tumor, clinical trial, hallmark,